ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
1.090
+0.010 (0.93%)
At close: May 15, 2026, 4:00 PM EDT
1.110
+0.020 (1.83%)
After-hours: May 15, 2026, 6:40 PM EDT
ABVC BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
26.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 509.59K | 357.16K | 234.31% |
| Dec 31, 2023 | 152.43K | -817.35K | -84.28% |
| Dec 31, 2022 | 969.78K | 613.99K | 172.57% |
| Dec 31, 2021 | 355.80K | -127.25K | -26.34% |
| Dec 31, 2020 | 483.05K | -218.67K | -31.16% |
| Dec 31, 2019 | 701.72K | 694.76K | 9,987.97% |
| Dec 31, 2018 | 6.96K | - | - |
| Dec 31, 2017 | - | - | - |
| Sep 30, 2017 | - | - | - |
| Dec 31, 2016 | 988.15K | - | - |
| Sep 30, 2016 | - | - | - |
| Dec 31, 2015 | 0 | - | - |
| Sep 30, 2015 | 3.36K | -4.43K | -56.85% |
| Sep 30, 2013 | 7.79K | 2.07K | 36.28% |
| Sep 30, 2012 | 5.71K | 2.52K | 79.12% |
| Sep 30, 2011 | 3.19K | -11.67K | -78.53% |
| Sep 30, 2010 | 14.86K | - | - |
| Sep 30, 2009 | - | - | - |
| Sep 30, 2008 | 25.09K | -16.58K | -39.78% |
| Sep 30, 2007 | 41.67K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Kyntra Bio | 7.44M |
| Dyadic International | 3.09M |
| Werewolf Therapeutics | 1.14M |
| Vistagen Therapeutics | 789.00K |
ABVC News
- 10 months ago - Sixteen new option listings on July 23rd - TheFly
- 1 year ago - ABVC BioPharma files $100M mixed securities shelf - TheFly
- 1 year ago - ABVC BioPharma believes ABV-1504 can fill void in market after Prozac - TheFly
- 1 year ago - ABVC BioPharma receives $200,000 cash payment from OncoX - TheFly
- 1 year ago - ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year - TheFly
- 1 year ago - ABVC BioPharma receives $50,000 in incremental licensing fees - TheFly
- 1 year ago - ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - GlobeNewsWire